Mirati Therapeutics Inc
Change company Symbol lookup
Select an option...
MRTX Mirati Therapeutics Inc
CRAI CRA International Inc
DUOT Duos Technologies Group Inc
CUZ Cousins Properties Inc
JRS Nuveen Real Estate Income Fund
GRTX Galera Therapeutics Inc
EVA Enviva Inc
SBLK Star Bulk Carriers Corp
TSP TuSimple Holdings Inc
GLG TD Holdings Inc
Go

Health Care : Biotechnology | Small Cap Blend
Company profile

Mirati Therapeutics Inc is a United States-based clinical-stage biotechnology company that is focused on bringing forward therapies that address areas of high unmet need, including lung cancer, and advancing a pipeline of novel therapeutics targeting the genetic and immunological drivers of cancer. The Company is using its scientific expertise to develop novel solutions in two registration-enabling programs: adagrasib (MRTX849), an investigational small molecule, potent and selective KRASG12C inhibitor, as monotherapy and in combination with other agents, and sitravatinib, an investigational spectrum-selective inhibitor of receptor tyrosine kinases in combination with checkpoint inhibitor therapies. The Company is also advancing its differentiated preclinical portfolio, including MRTX1133, an investigational KRASG12D inhibitor, MRTX1719, an investigational PRMT5 inhibitor, and other oncology discovery programs.

Price
Delayed
$52.80
Day's Change
-1.46 (-2.69%)
Bid
--
Ask
--
B/A Size
--
Day's High
53.55
Day's Low
52.10
Volume
(Above Average)

Today's volume of 438,855 shares is on pace to be greater than MRTX's 10-day average volume of 1,262,122 shares.

438,855

Display:

Providers:

UpdateCancel
6 providers
January 19, 2023
Mirati Announces IND Clearance by U.S. FDA Enabling Phase 1 Initiation for First-in-Class Oral KRASG12D Selective Inhibitor, MRTX1133

IND demonstrates Mirati's leadership in KRAS, representing the Company's third KRAS or KRAS-signaling program to enter clinical development Mirati Therapeutics, Inc. (NASDAQ: MRTX), announced today the U.S. Food and Drug Administration (FDA)has...(PR Newswire)

January 06, 2023
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 6 new employees with a grant date of January 3, 2023, as equity inducement awards outside of the...(PR Newswire)

Kaskela Law LLC Announces Investigation of Mirati Therapeutics, Inc. (MRTX) and Encourages Long-Term MRTX Investors to Contact the Firm

Philadelphia, Pennsylvania--(Newsfile Corp. - January 6, 2023) - Kaskela Law LLC announces that it is investigating Mirati Therapeutics, Inc. (NASDAQ: MRTX) on behalf of the company's long-term investors.(Newsfile)

December 22, 2022
Mirati Therapeutics to Present at the 41st Annual J.P. Morgan Healthcare Conference

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a commercial-stage targeted oncology company, today announced that the Company will present at the 41st J.P. Morgan Annual Healthcare Conference, on January 9, 2023. David Meek, chief executive officer, will...(PR Newswire)

December 21, 2022
Mirati announces Adagrasib (KRAZATI™) Receives Breakthrough Therapy Designation from FDA for Patients with Advanced, KRAS-Mutated Colorectal Cancer and NEJM Publishes Phase 1b/2 Data from Adagrasib With or Without Cetuximab in Colorectal Cancer

-- U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy Designation (BTD) for adagrasib (KRAZATITM) in combination with cetuximab in patients with KRASG12C-mutated advanced colorectal cancer (CRC) whose cancer has progressed...(PR Newswire)

December 13, 2022
Mirati Therapeutics Reports Inducement Grant Under NASDAQ Listing Rule 5635(c)(4)

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced that the company granted equity awards to 11 new employees with a grant date of December 1, 2022, as equity inducement awards outside of the...(PR Newswire)

QIAGEN receives FDA approval for companion diagnostic to Mirati Therapeutics' KRAZATI in non-small cell lung cancer

QIAGEN (NYSE:QGEN; Frankfurt Prime Standard: QIA) has announced the U.S. Food and Drug Administration (FDA) approval of its therascreen(R) KRAS RGQ PCR kit (therascreen KRAS kit) as a companion diagnostic test to Mirati Therapeutic's drug KRAZATI(R)...(BusinessWire)

December 12, 2022
Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics, Inc.(NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval forKRAZATI™(adagrasib), a targeted treatment option for adult patients with...(PR Newswire)

Mirati Therapeutics Announces U.S. FDA Accelerated Approval of KRAZATI™ (adagrasib) as a Targeted Treatment Option for Patients with Locally Advanced or Metastatic Non-Small Cell Lung Cancer (NSCLC) with a KRASG12C Mutation

Mirati Therapeutics, Inc.(NASDAQ: MRTX), a targeted oncology company, today announced that the U.S. Food and Drug Administration (FDA) has granted accelerated approval forKRAZATI™(adagrasib), a targeted treatment option for adult patients with...(PR Newswire)

December 05, 2022
Mirati Therapeutics Presents Late-Breaking Results Evaluating Concurrent Adagrasib and Pembrolizumab in First-Line Advanced/Metastatic Non-Small Cell Lung Cancer (NSCLC)

-- Adagrasib in combination with pembrolizumab demonstrates favorable tolerability and promising preliminary efficacy in patients with first-line advanced/metastatic NSCLC harboring a KRASG12C mutation (PR Newswire)

December 02, 2022
Mirati Therapeutics Announces Update for the Phase 3 SAPPHIRE Study

Evaluating Investigational Sitravatinib in Combination with Nivolumab for Patients with Non-Squamous Non-Small Cell Lung Cancer with Acquired Resistance to Chemotherapy and Immune Checkpoint Inhibitor Therapy (PR Newswire)

November 28, 2022
Mirati Therapeutics to Present Late-Breaking Combination Results and Host Virtual Investor Relations Event at ESMO IO

Mirati Therapeutics, Inc. (Nasdaq: MRTX), a clinical-stage targeted oncology company today announced a late-breaking presentation of concurrent combination results of adagrasib and pembrolizumab in first line advanced/metastatic non-small cell lung...(PR Newswire)

November 15, 2022
Biotech Sector Witnessing Growing Revenue Potential in Ongoing Battle Against Pancreatic Cancer

FN Media Group Presents USA News Group News Commentary Roughly five years after selling its flagship cancer asset Onivyde from to French biotech giant Ipsen S.A. for approximately $1 billion, Merrimack Pharmaceuticals, Inc. (NASDAQ:MACK) is still...(PR Newswire)

November 08, 2022
Mirati Therapeutics Reports Third Quarter 2022 Financial Results and Recent Corporate Updates

Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today reported financial results for the third quarter of 2022 and recent corporate updates. "In the third quarter, we made notable advancements within our...(PR Newswire)

Mirati Therapeutics Appoints Alan Sandler, M.D., as Executive Vice President and Chief Medical Officer, Shares Update to Executive Leadership Team

Charles M. Baum, M.D., Ph.D., President, Founder and head of R&D to retire 2Q 2023 following over a decade of Mirati leadership, driving corporate transformation Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology...(PR Newswire)

November 07, 2022
Incyte And Mirati Therapeutics Enter Into Clinical Trial Collaboration and Supply Agreement to Evaluate INCB99280 and Adagrasib in Patients with KRASG12C-Mutated Solid Tumors

Incyte (NASDAQ:INCY) and Mirati Therapeutics, Inc. (NASDAQ:MRTX), a clinical-stage targeted oncology company, today announced a clinical trial collaboration and supply agreement to investigate the combination of INCB99280, Incyte's small molecule...(BusinessWire)

Earnings Calendar and Events Data provided by |Terms of Use| © 2023 Wall Street Horizon, Inc.

Market data accompanied by is delayed by at least 15 minutes for NASDAQ, NYSE MKT, NYSE, and options. Duration of the delay for other exchanges varies.
Market data and information provided by Morningstar.

Options are not suitable for all investors as the special risks inherent to options trading may expose investors to potentially rapid and substantial losses.
Please read Characteristics and Risks of Standard Options before investing in options.

"Hot" indicates urgent and noteworthy news stories as determined by providers Dow Jones or Benzinga. TD Ameritrade does not select or recommend "hot" stories.

Information and news provided by ,, , Computrade Systems, Inc., ,, and

Copyright © 2023. All rights reserved.